Generic Drugs in the 21st Century: FDA’s Actions Create Transparency and Value for Complex Generic Product Development

By Robert Lionberger, PhD, Director of the Office of Research and Standards in CDER’s Office of Generic Drugs

Advancing complex generic drug development is an important part of FDA’s goal to help make sure patients have access to a broad range of potentially cost-saving medicines.

More with Robert Lionberger, PhD

 

Previous From Our Perspectives

• The Collection